�The US Food and Drug
Administration (FDA) has approved two single-pill combination medications,
Diovan HCT(R) (diovan and hydroDIURIL) and Exforge(R)
(amlodipine and valsartan), as initial or 'first-line' therapies in
patients likely to need multiple drugs to achieve their blood LC142% HCT, Tekturna, or Exforge have
generally been mild and brief. The most usual side effects with Diovan and
Diovan HCT ar headache and dizziness. A side effect experienced by more
patients taking Tekturna than patients taking a sugar pill was diarrhoea.
Side effects that occurred more oftentimes with Exforge than placebo are
gibbousness of the hands, ankles, or feet; nasal congestion or huffy throat;
straits or chest cold; and dizziness.
Disclaimer
The foregoing discharge contains forward-looking statements that can be
identified by terminology such as "whitethorn", "could", "potential", "suggests",
"will", "risk", "confidence", or standardized expressions, or by give tongue to or
implied discussions regarding potential future revenues from Diovan HCT and
Exforge. Such innovative statements reflect the current views of the
Company regarding succeeding events, and involve known and unknown risks,
uncertainties and early factors that may effort actual results with Diovan
HCT and Exforge to be materially different from any future results,
functioning or achievements expressed or implied by such statements. There
can be no guarantee that Diovan HCT and Exforge will achieve any particular
levels of revenue in the future. In finicky, management's expectations
regarding Diovan HCT and Exforge could be affected by, among other things,
the company's ability to obtain or maintain patent or early proprietary
noetic property tribute; competition in general; governing,
industry and general public pricing pressures; unexpected regulative
actions or delays or government regularisation generally; unexpected clinical
trial results, including unexpected new clinical information and unexpected
additional analysis of existing clinical information; and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Should nonpareil or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may diverge materially from those awaited,
believed, estimated or expected. Novartis is providing the information in
this weightlift release as of this date and does non undertake any obligation to
update whatever forward-looking statements contained in this press release as a
consequence of new information, future events or otherwise.
About Novartis
Novartis Pharmaceuticals Corporation researches, develops, manufactures
and markets leading modern prescription drugs used to treat a number of
diseases and conditions, including those in the cardiovascular, metabolic,
cancer, organ transplantation, central uneasy system, dermatological, GI
and respiratory areas. The company's mission is to ameliorate people's lives
by pioneering novel health care solutions.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals
Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides
healthcare solutions that speak the evolving needs of patients and
societies. Focused solely on growth areas in health care, Novartis offers a
diversified portfolio to best meet these of necessity: innovative medicines,
cost-saving generic pharmaceuticals, interference vaccines and diagnostic
tools, and consumer health products. Novartis is the only when company with
leading positions in these areas. In 2007, the Group's chronic
operations (excluding divestments in 2007) achieved net gross sales of USD 38.1
billion and net income of USD 6.5 billion. Approximately USD 6.4 one thousand million
was invested in R&D activities passim the Group. Headquartered in
Basel, Switzerland, Novartis Group companies employ approximately 98,000
full-time associates and operate in over cxl countries around the universe.
For more information, please visit hTTP://www.novartis.com.
Novartis Pharmaceuticals Corporation
http://www.novartis.com
View drug info on Diovan; Tekturna.
More info
